Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10258616
APP PUB NO 20180064705A1
SERIAL NO

15809829

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to prolonged release pharmaceutical dosage forms comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • EURO-CELTIQUE SA

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Danagher, Helen Kathleen Cambridge, GB 13 158
Hayes, Geoffrey Gerard Cambridge, GB 19 428
Krishnamurthy, Thinnayam Naganathan Scarborough, CA 4 10
Mohammad, Hassan Cambridge, GB 28 900
Vargas, Rincon Ricardo Alberto Mississauga, CA 18 45
Walden, Malcolm Cambridge, GB 27 315
Whitehouse, Jonathon Oliver Cambridge, GB 7 22

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 16, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 16, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00